Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01287195 · ClinicalTrials.gov registry record · Phase 1
Oral OKT3 for the Treatment of Active Ulcerative Colitis
A Phase 1 study of Ulcerative Colitis, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01287195: Completed Phase 1 study of Ulcerative Colitis, sponsored by Brigham and Women's Hospital.
NCT01287195 is a Phase 1 study of Ulcerative Colitis that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 6 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01287195, a Phase 1 study of Ulcerative Colitis, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the safety and efficacy of orally delivered short-term OKT3 in participants with active ulcerative colitis.
Primary Outcome
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which wo
Conditions Studied
Interventions
- DRUG Omeprazole
- DRUG Oral OKT3
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-04-07 |
| Est. Completion | 2013-05-02 |
| Phase | Phase 1 |
What the finished NCT01287195 record still lists
NCT01287195 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Omeprazole is the first listed.
NCT01287195 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01287195 about?
NCT01287195 is a clinical study titled "Oral OKT3 for the Treatment of Active Ulcerative Colitis". This study will assess the safety and efficacy of orally delivered short-term OKT3 in participants with active ulcerative colitis.
What is the current status of trial NCT01287195?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-04-07. Estimated completion is 2013-05-02.
What conditions does trial NCT01287195 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT01287195?
The interventions under investigation include: Omeprazole (DRUG), Oral OKT3 (DRUG).
Who is sponsoring clinical trial NCT01287195?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01287195 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01287195's enrollment target sits among peer trials
6 123rd of 122 the lowest of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
RECRUITING · Phase 1
-
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
RECRUITING · Phase 1
-
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
RECRUITING · Phase 1
-
CP101 for the Treatment of Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Angiographic Delivery of AD-MSC for Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI